| Name | Title | Contact Details |
|---|
Victory Pharma, Inc. is a specialty pharmaceutical company that acquires, markets and develops prescription pharmaceutical products that treat pain and related conditions. We market these products to health care professionals through our experienced US
Let’s operate. We prioritize you, so you can prioritize patients. Trusted brands like Quill, Sharpoint, and Tachosil.
At PharmMD, we believe every patient deserves personalized attention, the best information available, and reliable guidance from medical professionals to live a healthier life. This deeply held conviction guided our founder Fred McWhorter, an old-fashioned pharmacist who devoted more than 50 years to his passion of bringing health and healing to his customers–not simply selling medicine. Recognizing the value of emerging technology, he envisioned building a real-time information bridge between pharmacists (Pharm) and physicians (MD) to significantly improve patient treatment. Following Fred’s untimely death in 2005, his brother Clayton McWhorter, a veteran healthcare pioneer, brought Fred’s dream to fruition. In 2006, Clayton teamed with entrepreneur Samuel “Bo” Bartholomew to establish PharmMD in Nashville, TN. With the arrival of successful healthcare executive Robert Yeager as CEO in 2013, PharmMD pressed to the forefront in Medicare Part D Star Ratings improvement, as well as Medication Therapy Management (MTM) programs. Today PharmMD remains a leader in quality improvement and a healthcare industry innovator, delivering fast and effective solutions to CMS-regulated health plans and employer groups. Our pioneering technology, proprietary protocols and personalized patient profiles, combined with our outcomes-driven reporting, provide a catalyst for effective medication decisions; ultimately upholding Fred’s vision for improving lives. We exist to create a healthier world through the most effective use of the right medication.
Integrum has since its foundation been helping amputees towards an improved quality of life. We specialize in the osseointegration method.
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.